Katsuhiro Masago

Summary

Affiliation: Kyoto University
Country: Japan

Publications

  1. pmc Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial
    Shiro Fujita
    Institute of Biomedical Research and Innovation Hospital, 2 2 Minatojima Minami machi, Chuo Ku, Kobe, 650 0047, Japan
    BMC Cancer 12:185. 2012
  2. doi request reprint Effect of the BCL2 gene polymorphism on survival in advanced-stage non-small cell lung cancer patients who received chemotherapy
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Oncology 84:214-8. 2013
  3. doi request reprint Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
    Med Oncol 29:1614-21. 2012
  4. pmc Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy
    Shiro Fujita
    Division of Integrated Oncology, Institute of Biomedical Research and Innovation, 2 2 Minatojima Minami machi, Chuo Ku, Kobe, Japan
    BMC Med Genet 11:167. 2010
  5. doi request reprint Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto 606 8507 Japan
    Oncol Rep 26:795-803. 2011
  6. doi request reprint Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Japan
    Clin Lung Cancer 12:307-12. 2011
  7. doi request reprint Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Clin Lung Cancer 12:56-61. 2011
  8. doi request reprint Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I)
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Jpn J Clin Oncol 40:1105-9. 2010
  9. doi request reprint Phase I study of the combination of nedaplatin and gemcitabine in previously untreated advanced squamous cell lung cancer
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Syogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Chemother Pharmacol 67:325-30. 2011
  10. doi request reprint Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Syogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
    Med Oncol 28:351-6. 2011

Collaborators

Detail Information

Publications39

  1. pmc Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial
    Shiro Fujita
    Institute of Biomedical Research and Innovation Hospital, 2 2 Minatojima Minami machi, Chuo Ku, Kobe, 650 0047, Japan
    BMC Cancer 12:185. 2012
    ..We studied patients with advanced NSCLC for whom treatment was customized based on EGFR mutation status...
  2. doi request reprint Effect of the BCL2 gene polymorphism on survival in advanced-stage non-small cell lung cancer patients who received chemotherapy
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Oncology 84:214-8. 2013
    ..This study aimed to evaluate the association between BCL2 single-nucleotide polymorphisms and survival outcome in advanced non-small cell lung cancer (NSCLC)...
  3. doi request reprint Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
    Med Oncol 29:1614-21. 2012
    ..We demonstrate that having HGF-positive serum is predictive of a negative response to gefitinib therapy in patients with advanced NSCLC who harbor wild-type EGFR...
  4. pmc Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy
    Shiro Fujita
    Division of Integrated Oncology, Institute of Biomedical Research and Innovation, 2 2 Minatojima Minami machi, Chuo Ku, Kobe, Japan
    BMC Med Genet 11:167. 2010
    ..The aim of this study was to evaluate the influence of polymorphisms in the eNOS gene on prognosis of patients with advanced stage non-small-cell lung cancer (NSCLC)...
  5. doi request reprint Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto 606 8507 Japan
    Oncol Rep 26:795-803. 2011
    ..We also demonstrated that both IGF1-positive serum and wild-type EGFR were independent poor prognostic factors in patients with non-squamous NSCLC who received gefitinib therapy...
  6. doi request reprint Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Japan
    Clin Lung Cancer 12:307-12. 2011
    ..Thus, we investigated the pharmacokinetics (PK) of erlotinib and its active metabolite OSI-420 in non-small-cell lung cancer (NSCLC) of malignant pleural effusion (MPE)...
  7. doi request reprint Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Clin Lung Cancer 12:56-61. 2011
    ....
  8. doi request reprint Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I)
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Jpn J Clin Oncol 40:1105-9. 2010
    ..Therefore, we may suggest that this rare mutation (S768I in exon 20) may not be an insensitive epidermal growth factor receptor somatic mutation in vivo...
  9. doi request reprint Phase I study of the combination of nedaplatin and gemcitabine in previously untreated advanced squamous cell lung cancer
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Syogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Chemother Pharmacol 67:325-30. 2011
    ....
  10. doi request reprint Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Syogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
    Med Oncol 28:351-6. 2011
    ..The PIC/TAT ratio may become a surrogate marker for treatment with anticoagulants in the future...
  11. doi request reprint Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Cancer Sci 100:1917-22. 2009
    ..468; P = 0.0058), and the VEGF -1154AA and AG genotypes (HR, 1.419; 95% CI, 1.033-1.901; P = 0.0316) were significant independent prognostic factors for survival. In this study, polymorphisms in VEGF may affect survival in advanced NSCLC...
  12. doi request reprint Accuracy of epidermal growth factor receptor gene mutation analysis by direct sequencing method based on small biopsy specimens from patients with non-small cell lung cancer: analysis of results in 19 patients
    Katsuhiro Masago
    Department of Respiratory Medicine, Kyoto University Hospital, 54 Shogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
    Int J Clin Oncol 13:442-6. 2008
    ....
  13. doi request reprint Clinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Cancer Sci 99:2295-301. 2008
    ..894; P = 0.003) were significant independent prognostic factors. Our study demonstrates that the status of the serum EGFR ligand, in addition to EGFR activating mutation, is a predictive factor for response to gefitinib therapy...
  14. doi request reprint Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinib
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Sakyo ku, Kyoto, Japan
    Oncology 79:355-62. 2010
    ....
  15. doi request reprint Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    J Thorac Oncol 5:950-5. 2010
    ..We investigated CSF concentrations of erlotinib and its active metabolite OSI-420...
  16. doi request reprint Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    J Thorac Oncol 5:601-5. 2010
    ..Thus, we investigated the pharmacokinetics (PK) of erlotinib and its active metabolite OSI-420 in such patients with nonsmall cell lung cancer (NSCLC)...
  17. doi request reprint Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer
    Masahide Fukudo
    Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Sakyo ku, Kyoto, 606 8507, Japan
    Clin Pharmacokinet 52:593-609. 2013
    ..The secondary objective was to identify genetic determinant(s) for the cerebrospinal fluid (CSF) permeability of erlotinib and its active metabolite OSI-420...
  18. doi request reprint Association between vascular-poor area of primary tumors and epidermal growth factor receptor gene status in advanced lung adenocarcinoma
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo ku, Kyoto, 606 8507, Japan
    Med Oncol 29:3169-75. 2012
    ..As a consequence, evaluation using a combination of smoking status and vascular-poor area allows us to predict presence of EGFR mutations at a high frequency...
  19. doi request reprint Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Sakyo ku, Japan
    Cancer Chemother Pharmacol 70:399-405. 2012
    ..However, there has been no study in which cerebrospinal fluid (CSF) concentrations of gefitinib and erlotinib are directly compared. Thus, we aimed to compare them...
  20. doi request reprint Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitor
    Kaoru Irisa
    Department of Respiratory Medicine, National Cancer Center Hospital East, Tokyo, Japan
    Med Oncol 29:185-92. 2012
    ..These factors should be taken into consideration in the pretreatment assessment as important factors predicting survival outcome...
  21. doi request reprint Association of the transforming growth factor ß1 promoter polymorphism, C-509T, with smoking status and survival in advanced non-small cell lung cancer
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Oncol Rep 25:377-82. 2011
    ....
  22. doi request reprint Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Cancer 117:819-25. 2011
    ....
  23. doi request reprint Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
    Lung Cancer 74:98-102. 2011
    ..In contrast, the approved daily dose of gefitinib (250 mg) is only one-third of its MTD. Significantly different adverse events have been associated with gefitinib and erlotinib...
  24. doi request reprint Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer
    Young Hak Kim
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Sakyo ku, Kyoto, Japan
    Clin Lung Cancer 13:385-90. 2012
    ..The activities of IGF are strictly regulated by a family of IGF binding proteins (IGFBP), especially IGFBP3, a major serum carrier protein for IGF...
  25. pmc Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto, 606 8507, Japan
    Cancer Chemother Pharmacol 68:1089-92. 2011
    ..We investigated the plasma and CSF concentrations of erlotinib at each dose as well as the correlation between the plasma and CSF concentrations of erlotinib...
  26. doi request reprint Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo ku, Kyoto 606 8507, Japan
    Lung Cancer 77:464-8. 2012
    ..Many patients received corticosteroids during retreatment, but not the one with recurrence of ILD. This may suggest that corticosteroids can prevent recurrence due to their antiinflammatory properties...
  27. doi request reprint Long-term survival in a patient with small-cell lung cancer undergoing hemodialysis who received multiple courses of chemotherapy
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto 606 8507, Japan
    Jpn J Clin Oncol 41:582-5. 2011
    ....
  28. doi request reprint Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Clin Lung Cancer 13:304-11. 2012
    ..However, pneumonitis associated with chemotherapy was significantly increased in patients with preexisting ILD, and preexisting ILD is an independent prognostic factor for poorer survival...
  29. doi request reprint Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small-cell lung cancer
    Yuichi Sakamori
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Cancer Sci 103:1065-70. 2012
    ..The correlation with clinical response to chemotherapy provides further support for the biologic relevance of these cells in patients' prognosis and highlights the potential use of CEPs as therapeutic targets...
  30. doi request reprint Two cases of cancer-associated retinopathy combined with small-cell lung cancer
    Yuichi Sakamori
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Jpn J Clin Oncol 41:669-73. 2011
    ..When cancer-associated retinopathy is suspected, a comparatively large quantity of steroids and anticancer treatment should be combined immediately...
  31. doi request reprint Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902
    Young Hak Kim
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Chemother Pharmacol 70:271-6. 2012
    ....
  32. ncbi request reprint Octreotide, a somatostatin analogue, in the treatment of chylothorax associated with idiopathic fibrosing mediastinitis
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University
    Tohoku J Exp Med 222:51-3. 2010
    ..After discharge, the patient has received octreotide treatment for 6 months without serious adverse events. We suggest octreotide as a treatment option for FM...
  33. doi request reprint Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo
    Hiroki Nagai
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto 606 8507, Japan
    Int J Oncol 41:24-30. 2012
    ..These findings suggest that NO donors, such as NOC-18 and GTN, enhance the anticancer effects of PEM by increasing the RFC1 and FPGS expression and stimulating cGMP signaling pathways in cancer cells...
  34. doi request reprint Pulmonary embolism due to internal jugular vein thrombosis in a patient with non-small cell lung cancer receiving bevacizumab
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaracho, Sakyo ku, Kyoto, 606 8507, Japan
    Int J Clin Oncol 16:444-6. 2011
    ..In this article, we present a rare case of non-small cell lung cancer complicated by pulmonary embolism due to internal jugular vein thrombosis associated with bevacizumab...
  35. doi request reprint Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma
    Katsuhiro Masago
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Int J Cancer 124:2744-9. 2009
    ..Our data suggest that EGFR-tyrosine-kinase inhibitors may deserve consideration in the treatment of a subset of patients with PTC, just as with pulmonary adenocarcinoma...
  36. ncbi request reprint Elevation of serum thioredoxin in patients with gefitinib-induced interstitial lung disease
    Keiichiro Sakuma
    Department of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto
    Intern Med 46:1905-9. 2007
    ..However, the mechanism still remains unclear. The objective of this study was to examine whether or not oxidative stress, one of the common factors in drug-associated ILD, is involved in the pathogenesis of gefitinib-induced ILD...